Zoryve (roflumilast) topical foam has shown promising results in clinical trials for treating seborrheic dermatitis. Here are some key points:

- Effectiveness: After eight weeks, 80% of users achieved clear or almost clear skin, with 50% showing complete clearance of symptoms
- Symptom Relief: Significant reduction in Show Full Answer

Zoryve (roflumilast) topical foam has shown promising results in clinical trials for treating seborrheic dermatitis. Here are some key points:

- Effectiveness: After eight weeks, 80% of users achieved clear or almost clear skin, with 50% showing complete clearance of symptoms.
- Symptom Relief: Significant reduction in itch, redness, and scaling, with over 60% experiencing a four-point reduction in itch severity.
- Onset of Action: Some users reported improvement within two days.
- Safety: Generally well-tolerated with common side effects including nasopharyngitis, nausea, and headache.

For more details, visit [MySebDermTeam](https://www.MySebDermTeam.com/resources/fda-app...).

 This AI-generated response comes from MySebDermTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

FDA Approves Zoryve Foam To Treat Seborrheic Dermatitis | MySebDermTeam

Zoryve Topical Foam (Roflumilast ) for Sebhorreic Dermatitis | MySebDermTeam